Revisiting gene mutations and prognosis of ex-M6a-acute erythroid leukemia with regard to the new WHO classification

por Cervera, N, Carbuccia, N, Mozziconacci, M-J, Adélaïde, J, Garnier, S, Guille, A, Murati, A, Chaffanet, M, Vey, N, Birnbaum, D, Gelsi-Boyer, V
Publicado 2017

Mutations and deletions of the SUZ12 polycomb gene in myeloproliferative neoplasms

por Brecqueville, M, Cervera, N, Adélaïde, J, Rey, J, Carbuccia, N, Chaffanet, M, Mozziconacci, M J, Vey, N, Birnbaum, D, Gelsi-Boyer, V, Murati, A
Publicado 2011

Drug response profiling can predict response to ponatinib in a patient with t(1;9)(q24;q34)-associated B-cell acute lymphoblastic leukemia

por Collette, Y, Prébet, T, Goubard, A, Adélaïde, J, Castellano, R, Carbuccia, N, Garnier, S, Guille, A, Arnoulet, C, Charbonier, A, Mozziconacci, M J, Birnbaum, D, Chaffanet, M, Vey, N
Publicado 2015

A chemogenomic approach to identify personalized therapy for patients with relapse or refractory acute myeloid leukemia: results of a prospective feasibility study

por Collignon, A., Hospital, M. A., Montersino, C., Courtier, F., Charbonnier, A., Saillard, C., D’Incan, E., Mohty, B., Guille, A., Adelaïde, J., Carbuccia, N., Garnier, S., Mozziconacci, M. J., Zemmour, C., Pakradouni, J., Restouin, A., Castellano, R., Chaffanet, M., Birnbaum, D., Collette, Y., Vey, N.
Publicado 2020